The following trials are currently enrolling patients:
Epithelial ovarian cancer
A randomized, double-blind, phase 3 comparison of platinum-based therapy with TSR-042 and niraparib versus standard care platinum-based therapy as first-line treatment of stage III or IV nonmucinous epithelial ovarian cancer.
Principal investigator: Loukovaara Mikko
HUS Helsinki University Hospital, Department of Obstetrics and Gynecology
email: mikko.loukovaara@hus.fi
Prostate cancer
STESIDES
Open, non-randomised, uncontrolled, multicenter dose-escalation, firts-in-human study with a dose expansion. Safety and pharmacokinetics of ODM-209 in patients with matastatic castration-resostant prostate cancer or estrogen receptor- positive, HER2 negative advanced breast cancer.
Principal investigator: Utriainen Tapio
HUS Helsinki University Hospital, Comprehensive Cancer Center
Contact information: HUS Helsinki University Hospital, Comprehensive Cancer Center
email: haluantutkimuspotilaaksi@hus.fi
CYPIDES
Safety and pharmacokinetics of ODM-208 in patients with metastatic castration-resistant prostate cancer.
Principal investigator: Utriainen Tapio
HUS Helsinki University Hospital, Comprehensive Cancer Center
Contact information: HUS Helsinki University Hospital, Comprehensive Cancer Center
email: haluantutkimuspotilaaksi@hus.fi
THORIUM PSMA
A Phase 1, open label, first in human, multi center, study to evaluate the safety, tolerability, pharmacokinetics and anti tumor activity of a thorium-227 labeled antibody-chelator conjugate BAY 2315497 injection, in patient with metastatic castration resistent prostate cancer
Principal investigator: Vaalavirta Leila
HUS Helsinki University Hospital, Comprehensive Cancer Center
Contact information: HUS Helsinki University Hospital, Comprehensive Cancer Center
email: haluantutkimuspotilaaksi@hus.fi
HERO
Randomized, open-label, parallel group efficacy and safety study to evaluate oral daily relugolix 120 mg to Leuprolide in patients with androgen-sensitive advanced prostate
Principal investigator: Taari Kimmo
HUS Helsinki University Hospital, Abdominal Center, Urology
Contact information: Study nurse +358 50 247 1345
LIDDS
A Single Blind, Two-Stage Dose Finding Study to Evaluate the Safety, Tolerability and Efficacy of a Single Liproca® Depot Injection into the Prostate in Patients with Localized Prostate Cancer, Assigned to Active Surveillance who are at High Risk for Disease Progression (followed by an Open Label Extension with a Repeat Injection (Optional)
Principal investigator: Antti Rannikko
HUS Helsinki University Hospital, Abdominal Center, Urology
Contact information: Study nurse + 358 50 247 1345
ProScreen
A Randomized Trial of Early Detection of Clinically Significant Prostate Cancer (ProScreen) (ProScreen)
Principal investigator: Antti Rannikko
HUS Helsinki University Hospital, Abdominal Center, Urology
Contact information: Study nurse + 358 50 247 1345
PRIAS
Prostate cancer Research International: Active Surveillance – guideline and study for the expectant management of localized prostate cancer with curative intent
Principal investigator: Antti Rannikko
HUS Helsinki University Hospital, Abdominal Center, Urology
Contact information: Study nurse +358 50 247 1345
SPCG-15
Primary Radical Prostatectomy Versus Primary Radiotherapy for Locally Advanced Prostate Cancer: an Open Randomized Clinical Trial
Principal investigator: Antti Rannikko
HUS Helsinki University Hospital, Abdominal Center, Urology
Contact information: Study nurse +358 50 247 1345
RAMPP
Multicentric, Prospective, Randomized Controlled Trial Comparing Best Systemic Therapy (BST) With Radical Prostatectomy or BST Alone in the Management of Men With Pauci-metastatic Prostate Cancer
Principal investigator: Antti Rannikko
HUS Helsinki University Hospital, Abdominal Center, Urology
Contact information: Study nurse +358 50 247 1345
DEDUCER
Development of Diagnostics and Treatment of Urological Cancers
Principal investigator: Antti Rannikko
HUS Helsinki University Hospital, Abdominal Center, Urology
Contact information: Study nurse +358 50 247 1345
FinnBladder 9
Treatment of Ta Bladder Cancer in High Risk of Recurrence – Fluorescence Cystoscopy With Optimized Adjuvant Mitomycin-C
Principal investigator: Riikka Järvinen
HUS Helsinki University Hospital, Abdominal Center, Urology
Contact information: Study nurse +358 50 247 1345
GIST ( Gastro Intestinal Stromal Tumor)
The stop-GIST-trial
Discontinuation of imatinib in patients with oligo-metastatic gastrointestinal stromal tumor that has become radiologically undetectable with treatment. A prospective multicenter phase II trial
Principal investigator: Katriina Peltola
HUS Helsinki University Hospital, Comprehensive Cancer Center
Contact information: HUS Helsinki University Hospital, Comprehensive Cancer Center
email: haluantutkimuspotilaaksi@hus.fi
SSGXXII
A randomized phase II trial of imatinib alternating with regorafenib compared to imatinib alone for the first line treatment of advanced gastrointestinal stromal tumor (GIST)
Principal investigator: Katriina Peltola
HUS Helsinki University Hospital, Comprehensive Cancer Center
Contact information: HUS Helsinki University Hospital, Comprehensive Cancer Center
email: haluantutkimuspotilaaksi@hus.fi
Cholangiocarcinoma
FIGHT-302
A phase 3, open-label, randomized, active-controlled, multicenter study to evaluate the efficacy and safety og pemigatinib versus cemsitabine plus cisplatin chemotherapy in firts-line threatment of participants with unresectable or metastatic cholangiocarcinoma with FGFR2 rearrangement FIGHT-302
Principal investigator: Katriina Peltola
HUS Helsinki University Hospital, Comprehensive Cancer Center
Contact information: HUS Helsinki University Hospital, Comprehensive Cancer Center
email: haluantutkimuspotilaaksi@hus.fi
Solid tumor
MATINS
A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients
Principal investigator: Annika Pasanen
HUS Helsinki University Hospital, Comprehensive Cancer Center
Contact information: HUS Helsinki University Hospital, Comprehensive Cancer Center
email: haluantutkimuspotilaaksi@hus.fi
Origin of tumour unknown (NUD)
CUPISCO
A phase II, randomized, active-controlled, multi-center study comparing the efficacy and safety of targeted therapy or cancer immunotherapy guided by genomic profiling versus platinum-based chemotherapy in patients with cancer of unknown primary site who have received three cycles of platinum douplet chemotherapy
Principal investigator: Pia Suonpää
HUS Helsinki University Hospital, Comprehensive Cancer Center
Contact information: HUS Helsinki University Hospital, Comprehensive Cancer Center
email: haluantutkimuspotilaaksi@hus.fi
Lung cancer
THORIUM
An open-label, firts-in-human, multi-center study to evaluate the safety, tolerability, pharmocokinetics and anti-tumor activity of thorium-227 labeled antibody-chelator conjugate, BAY 2287411 injection, in patients with solid tumors known to express mesothelin
Principal investigator: Vaalavirta Leila
HUS Helsinki University Hospital, Comprehensive Cancer Center
Contact information: HUS Helsinki University Hospital, Comprehensive Cancer Center
email: haluantutkimuspotilaaksi@hus.fi
Lymphoma
ENRICH
Randomized, open label study of Rituximab / Ibrutinib vs Rituximab / Chemotherapy in older patients with untreated mantel cell lymphoma.
Principal investigator: Annika Pasanen
HUS Helsinki University Hospital, Comprehensive Cancer Center
Contact information: HUS Helsinki University Hospital, Comprehensive Cancer Center
email: haluantutkimuspotilaaksi@hus.fi
NP30179
A Multicenter, open-label, phase I study to evaluate the safety, tolerability and pharmacokinetics of
escalating doses of RO7082859 as a single agent and in combination with obinutuzumab administered
after a fixed, single dose pre-treatment of obinutuzumab ( Gazyva/ Gazyvaro ) in patient with relapsed /
refractory B-cell Non Hodgin`s Lymphoma.
Principal investigator: Sirpa Leppä
HUS Helsinki University Hospital, Comprehensive Cancer Center
Contact information: HUS Helsinki University Hospital, Comprehensive Cancer Center
email: haluantutkimuspotilaaksi@hus.fi
BIO-CHIC
Biomarker driven and dose intensified chemoimmunotherapy with early CNS prophylaxis in patients less than 65 years with high risk diffuse large B-cell lymphoma
Principal investigator: Sirpa Leppä
HUS Helsinki University Hospital, Comprehensive Cancer Center
Contact information: HUS Helsinki University Hospital, Comprehensive Cancer Center
email: haluantutkimuspotilaaksi@hus.fi
PREBEN
A phase 1/2 study of combination of pixantrone, etoposide, bendamustine and in CD-20 positive tumors, rituximab in patients with relapsed aggressive non-Hodgkin lymphomas of B- or T- cell phenotype- The PREBEN study
Principal investigator: Sirpa Leppä
HUS Helsinki University Hospital, Comprehensive Cancer Center
Contact information: HUS Helsinki University Hospital, Comprehensive Cancer Center
email: haluantutkimuspotilaaksi@hus.fi
CHRONOS-4
A phase III, randomized, double-blind, controlled, multicenter study of intravenous PI3K inhibitor copanlisib in combination with standard immunochemotherapy versus standard immunochemotherapy in patients with relapsed indolent non-Hodgkin’s lymphoma (iNHL)- CHRonos-4
Principal investigator: Sirpa Leppä
HUS Helsinki University Hospital, Comprehensive Cancer Center
Contact information: HUS Helsinki University Hospital, Comprehensive Cancer Center
email: haluantutkimuspotilaaksi@hus.fi
JCAR
A phase 2, single-arm, multi-cohort, multi-center trial to determine the efficacy and safety of JCAR017 in adult subjects with aggressive B-cell Non-Hodgkin lymphoma
Principal investigator: Sirpa Leppä
HUS Helsinki University Hospital, Comprehensive Cancer Center
Contact information: HUS Helsinki University Hospital, Comprehensive Cancer Center
email: haluantutkimuspotilaaksi@hus.fi
LYMRIT
A phase I/II study of lutetium (177Lu)-lilotomab satetraxetan (Betalutin®) antibody-radionuclide-conjugate for treatment of relapsed non-Hodgkin lymphoma.
Principal investigator: Sirpa Leppä
HUS Helsinki University Hospital, Comprehensive Cancer Center
Contact information: HUS Helsinki University Hospital, Comprehensive Cancer Center
email: haluantutkimuspotilaaksi@hus.fi
TRIANGLE
Autologous Transplantation after rituximab/Ibrutinib/Ara-c containig induction generalized mantle cell lymphoma- a randomized European mcl network trial
Principal investigator: Sirpa Leppä
HUS Helsinki University Hospital, Comprehensive Cancer Center
Contact information: HUS Helsinki University Hospital, Comprehensive Cancer Center
email: haluantutkimuspotilaaksi@hus.fi
SAKK 35/14
Rituximab with or without Ibrutinib for untreated patients with advanced follicular lymphoma in need of therapy. A randomized, double-blinded, SAKK and NLGcollaborative Phase II trial.
Principal investigator: Micaela Hernberg
HUS Helsinki University Hospital, Comprehensive Cancer Center
Contact information: HUS Helsinki University Hospital, Comprehensive Cancer Center
email: haluantutkimuspotilaaksi@hus.fi
Kidney cancer
COSMIC XL184-313
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab
and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously
Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk.
Principal investigator: Katriina Peltola
HUS Helsinki University Hospital, Comprehensive Cancer Center
Contact information: HUS Helsinki University Hospital, Comprehensive Cancer Center
email: haluantutkimuspotilaaksi@hus.fi
Melanoma
CA224-047
A randomized, douple-blind, phase 2/3 study of relatlimab combined with nivolumab versus nivolumab
in participants with previously untreated metastatic or unresectable melanoma.
Principal investigator: Micaela Hernberg
HUS Helsinki University Hospital, Comprehensive Cancer Center
Contact information: HUS Helsinki University Hospital, Comprehensive Cancer Center
email: haluantutkimuspotilaaksi@hus.fi
CA224-020
A Phase 1/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016)
Administered Alone and in Combination with Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors
Principal investigator: Katriina Peltola
HUS Helsinki University Hospital, Comprehensive Cancer Center
Contact information: HUS Helsinki University Hospital, Comprehensive Cancer Center
email: haluantutkimuspotilaaksi@hus.fi
CA209-76K
A Phase III randomized, double-blind study of adjuvant immunotherapy with nivolumab versus
placebo after complete resection of tage IIB/ C melanoma
Principal investigator:
HUS Helsinki University Hospital, Comprehensive Cancer Center
Contact information: HUS Helsinki University Hospital, Comprehensive Cancer Center
email: haluantutkimuspotilaaksi@hus.fi
Breast cancer
BORI
An open label, phase Ib, dose-escalation study evaluating the safety and tolerability of xentuzumab and abemaciclib in patients with locally advanced or metastatic solid tumors and in combination with endocrine therapy in patient with locally advenced or metastatic hormone receptor HER2-, breast cancer, followed by expansion cohorts.
Principal investigator: Meri Utriainen
HUS Helsinki University Hospital, Comprehensive Cancer Center
Contact information: HUS Helsinki University Hospital, Comprehensive Cancer Center
email: haluantutkimuspotilaaksi@hus.fi
STESIDES
Open, non-randomised, uncontrolled, multicenter dose-escalation, firts-in-human study with a dose expansion. Safety and pharmacokinetics of ODM-209 in patients with matastatic castration-resostant prostate cancer or estrogen receptor- positive, HER2 negative advanced breast cancer
Principal investigator: Tapio Utriainen
HUS Helsinki University Hospital, Comprehensive Cancer Center
Contact information: HUS Helsinki University Hospital, Comprehensive Cancer Center
email: haluantutkimuspotilaaksi@hus.fi
CLEE011A2207
A phase II, multicenter, randomized, open-label study to evaluate the safety and efficacy of 400mg of ribociclib in combination with non-steroidal aromatase inhibitors for the treatment of pre- and postmenopausal women with hormone receptor-positive, HER2 negative advanced breast cancer who received no prior therapy for advanced disease
Principal investigator: Tytti Ahola
HUS Helsinki University Hospital, Comprehensive Cancer Center
Contact information: HUS Helsinki University Hospital, Comprehensive Cancer Center
email: haluantutkimuspotilaaksi@hus.fi
BOLD
A randomized phase III study comparing trastuzumab, pertuzumab plus docetaxel (TPD) followed by 3 cycles of chemotherapy to the current standard regimen as the treatments of early HER2-positive breast cancer.
Principal investigator: Heikki Joensuu
HUS Helsinki University Hospital, Comprehensive Cancer Center
Contact information: HUS Helsinki University Hospital, Comprehensive Cancer Center
email: haluantutkimuspotilaaksi@hus.fi
IMPASSION
A phase III, randomized, double-blind, placebo-controlled, multicentre study of the efficacy and safety of atezolizumab plus chemotherapy for patients with early relapsing recurrent (inoperable locally advanced or metastatic) triple-negative breast cancer
Principal investigator: Meri Utriainen
HUS Helsinki University Hospital, Comprehensive Cancer Center
Contact information: HUS Helsinki University Hospital, Comprehensive Cancer Center
email: haluantutkimuspotilaaksi@hus.fi
A Randomized, Open-Label, Phase 3 Study of Abemaciclib combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage,Hormone Receptor Positive,Human Epidermal Receptor 2 Negative, Breast Cancer
Principal investigator: Paul Nyandoto
Päijät-Häme Central Hospital, oncology outpatient clinic, Lahti
Contact information: +358 3 819 4741 (study nurse)
BOLD
A Randomized Phase III Study Comparing Trastuzumab, Pertuzumab plus Docetaxel ( TPD) Followed by 3 Cycles of Chemotherapy to the Current Standard Regimen as the Treatments of Early HER2-positive Breast Cancer
Päätutkija: Paul Nyandoto
Päijät-Häme Central Hospital, oncology outpatient clinic, Lahti
Contact information: +358 3 819 4741 (study nurse)
Colorectal cancer
No studies recruiting patients are currently ongoing for colorectal cancer
ALL – Acute lymphatic leukemia
Ponatinib-3001
An Efficacy Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Participants With Newly Diagnosed Ph+ ALL.
Principal investigator: Kimmo Porkka
HUS Helsinki University Hospital, Comprehensive Cancer Center
Contact information: HUS Helsinki University Hospital, Comprehensive Cancer Center
EWALL-INO
Study of Inotuzumab Ozogamicin (INO) Combined to Chemotherapy in Older Patients with Philadelphia Chromosomenegative CD22+ B-cell Precursor Acute Lymphoblastic Leukemia.
Principal investigator: Ulla Wartiovaara-Kautto
HUS Helsinki University Hospital, Comprehensive Cancer Center
Contact information: HUS Helsinki University Hospital, Comprehensive Cancer Center
NOPHO-ALL 2008
Treatment Protocol for 16-45 years of age with Acute Lymphoblastic Leukemia patients. Same treatment protocol for 1-45 years of age patients.
Principal investigator: Ulla Wartiovaara-Kautto
HUS Helsinki University Hospital, Comprehensive Cancer Center
Contact information: HUS Helsinki University Hospital, Comprehensive Cancer Center
AML – Acute myeloid leukemia
CHDM201H12101C
Open-label study of HDM201 in combination with MBG453 or venetoclax in adult subjects with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS).
Principal investigator: Kimmo Porkka
HUS Helsinki University Hospital, Comprehensive Cancer Center
Contact information: HUS Helsinki University Hospital, Comprehensive Cancer Center
CPDR001X2105
Open-label study of PDR001 and/or MBG453 in combination with decitabine in patients with acute myeloid leukemia or high risk myelodysplastic syndrome.
Principal investigator: Kimmo Porkka
HUS Helsinki University Hospital, Comprehensive Cancer Center
Contact information: HUS Helsinki University Hospital, Comprehensive Cancer Center
HO150, AMLSG 29-18
Open, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib or enasidenib in combination with induction therapy and consolidation therapy followed by maintenance therapy in patients with newly diagnosed acute myeloid leukemia or myelodysplastic syndrome with excess blasts-2, with an IDH1 or IDH2 mutation, respectively, eligible for intensive chemotherapy.
Principal investigator: Mika Kontro
HUS Helsinki University Hospital, Comprehensive Cancer Center
Contact information: HUS Helsinki University Hospital, Comprehensive Cancer Center
VenEx, FLG-V001
Open-Label Study of Venetoclax in Combination With Azacytidine in Acute Myeloid Leukemia Patients Selected Using Ex Vivo Drug Sensitivity Screening.
Principal investigator: Mika Kontro
HUS Helsinki University Hospital, Comprehensive Cancer Center
Contact information: HUS Helsinki University Hospital, Comprehensive Cancer Center
MDS
Assesment of the possibilities of molecular medicine in sensitive diagnostics and personalized therapy response evaluation in myelodysplastic syndromes and related myeloid malignancies (MDS-MOLE-2015).
Principal investigator: Freja Ebeling
HUS Helsinki University Hospital, Comprehensive Cancer Center
Contact information: HUS Helsinki University Hospital, Comprehensive Cancer Center
Myeloma
CC-92480-MM-001
Open-label study to assess the safety, pharmacokinetics and preliminary efficacy of CC-92480 in combination with dexamethasone in subjects with relapsed and refractory multiple myeloma.
Principal investigator: Pekka Anttila
HUS Helsinki University Hospital, Comprehensive Cancer Center
Contact information: HUS Helsinki University Hospital, Comprehensive Cancer Center
IRd, NMSG#23/15
A study of ixazomib plus lenalidomide plus dexamethasone (IRd) treatment for newly diagnosed transplant eligible patients
Principal investigator: Raija Silvennoinen
Contact information: HUS Helsinki University Hospital, Comprehensive Cancer Center
HUS Helsinki University Hospital, Comprehensive Cancer Center
CLL – Chronic lymphatic leukemia
ASSURE
Single-Arm Multicenter Study of Acalabrutinib (ACP-196) in Subjects With Chronic Lymphocytic Leukemia.
Principal investigator: Vesa Lindström
HUS Helsinki University Hospital, Comprehensive Cancer Center
Contact information: HUS Helsinki University Hospital, Comprehensive Cancer Center
CML – Chronic myeloid leukemia
DASTOP2 (NordCML11) (Nordic CML Study Group)
Persistence of major molecular remission (MR3) in chronic myeloid leukemia after a second stop of TKI treatment in patients who failed an initial stop attempt. DASTOP2
Principal investigator: Satu Mustjoki
HUS Helsinki University Hospital, Comprehensive Cancer Center
Contact information: HUS Helsinki University Hospital, Comprehensive Cancer Center
BosuPeg (NordCML012) (Nordic CML Study Group) Phase III
Long-acting low dose Ropeginterferon in patients with chronic myeloid leukemia treated with Bosutinib from diagnosis.
Principal investigator: Perttu Koskenvesa
HUS Helsinki University Hospital, Comprehensive Cancer Center
Contact information: HUS Helsinki University Hospital, Comprehensive Cancer Center
Sickle Cell Disease
STAND
A Phase III, Multicenter, Randomized, Double-blind Study to Assess Efficacy and Safety of Crizanlizumab, With or Without Hydroxyurea/ Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients With Vaso-Occlusive Crises (STAND)
Principal investigator: Ulla Wartiovaara-Kautto
HUS Helsinki University Hospital, Comprehensive Cancer Center
Contact information: HUS Helsinki University Hospital, Comprehensive Cancer Center
Pediatric clinical trials
ALL – ACUTE LYMPHOPLASTIC LEUKEMIA
NOPHO-ALL 2008: Treatment Protocol for Children (1.0 – 17.9 years of age) and young adults (18-45 years of age) with Acute Lymphoblastic Leukemia
Hoito-ohjelma akuuttia lymfoblastileukemiaa sairastaville lapsille (1.0-17.9 vuoden ikäisille) ja nuorille aikuisille (18-45 vuoden ikäisille)
Tutkimuksessa verrattiin satunnaistetusti tehostettua alkuhoidon jälkeistä merkaptopuriinihoitoa tavanomaiseen ja jaksoittaista asparaginaasihoitoa tavanomaiseen jatkuvaan hoitoon. Tutkimuksen perusteella tehostettu merkaptopuriinihoito ei parantanut hoitotuloksia ja jaksoittainen asparaginaasihoito aiheutti vähemmän haittoja kuin jatkuva hoito, joten nämä hoidot ovat tällä hetkellä (2018) ALL:n käypä hoito tässä potilasryhmässä.
Principal investigator: Kim Vettenranta
HUS Helsinki University Hospital, Comprehensive Cancer Center, Childern’s Hospital
ALL – ACUTE LYMPHOPLASTIC LEUKEMIA
TEAM: A phase I-II study of 6-Thioguanine in Combination with Methotrexate and 6-Mercaptopurine during maintenance 2 therapy of childhood, adolescent and adult Acute Lymphoblastic Leukemia
Faasin I-II tutkimus 6-tioguaniinin, metotreksaatin ja merkaptopuriinin yhdistelmähoidosta akuutin lymfoblastileukemian ylläpitohoidossa
Kyseessä on kansainvälinen monikeskustutkimus, jonka tavoitteena on tutkia voidaanko akuutin lymfoblastileukemian ylläpitohoidon tehoa parantaa lisäämättä hoidon sivuvaikutuksia lisäämällä tavanomaisen merkaptopuriinin ja metotreksaatin yhdistelmään 6-tioguaniini -lääkitys.
Principal investigator: Jukka Kanerva
HUS Helsinki University Hospital, Comprehensive Cancer Center, Childern’s Hospital
ALL relapsed – ACUTE LYMPHOPLASTIC LEUKEMIA
InReALL SR 2010: International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010; A randomized Phase III Study Conducted by the Resistant Disease Committee of the International BFM Study Group
Uusiutuneen lapsuusiän lymfoblastilymfooman standardi riskin tautimuodon kansainvälinen hoitotutkimus
Tutkimuksen tarkoituksena on satunnaistetusti verrata kahta vakiintunutta solunsalpaajahoito-ohjelmaa uusiutuneen akuutin lymfoblastileukemian standardiriskin tautimuodon hoidossa (saksalaisperäinen BFM-ohjelma ja englantilainen mitoksantronipohjainen R3-ohjelma). Lisäksi kummassakin tutkimushaarassa tutkitaan satunnaistetusti parantaako solunsalpaajahoitoon lisätty leukemiasoluihin kohdistettu CD22 vasta-ainehoito epratutsumabi hoitotuloksia.
Principal investigator: Päivi Lähteenmäki Turku, Mervi Taskinen HUS
HUS Helsinki University Hospital, Comprehensive Cancer Center, Childern’s Hospital
INTERFANT ALL – ACUTE LYMPHOBLASTIC LEUKEMIA
INTERFANT-06: INTERNATIONAL COLLABORATIVE TREATMENT PROTOCOL FOR INFANTS UNDER ONE YEAR WITH ACUTE LYMPHOBLASTIC OR BIPHENOTYPIC LEUKEMIA
Kansainvälinen monikeskus / hoitotutkimus alle 1 vuotiaille akuuttia lymfoblastileukemiaa (ALL) tai bifenotyyppistä leukemiaa sairastaville lapsille
Tutkimuksen perushoitona on Interfant-99 hoitokaavion solunsalpaaja ohjelma uudella hoitojaksolla vahvistettuna. Tätä verrataan toiseen hoito-ohjelmaan, jossa tämän sijasta käytetään kahta ns. myeloista solunsalpaajajaksoa. Hoitoryhmät määritellään iän, valkosolujen määrän ja kromosomilöydösten perusteella.
Principal investigator: Olli Lohi Tampere, Kirsi Jahnukainen HUS
HUS Helsinki University Hospital, Comprehensive Cancer Center, Childern’s Hospital
AML – ACUTE MYELOID LEUKEMIA
Research study for treatment of children and adolescents with acute myeloid leukaemia 0-18 years, NOPHO-DBH AML 2012 Protocol
Lasten ja nuorten akuutin myeloisen AML leukemian lääketutkimus NOPHO-DBH 2012
Tutkimuksen tarkoitus on selvittää voidaanko taudin uusiutumisen riskiä pienentää parantamalla kahden ensimmäisen solunsalpaajahoidon riskiä vertaamalla onko DaunoXome tehokkaampi antrasykliini solunsalpaaja kuin Mitoxantrone sekä onko FLADx tehokkaampi solunsalpaajayhdistelmä kuin ADxE. Hoitojaksot valitaan randomisaatioilla.
Principal investigator: Kirsi Jahnukainen
HUS Helsinki University Hospital, Comprehensive Cancer Center, Childern’s Hospital
EWING SARCOMA
Ewing 2008: Study in Localized and Disseminated Ewing Sarcoma
Ewing 2008: Paikallisen ja levinneen Ewingin sarkooman hoitotutkimus
Satunnaistetussa hoitotutkimuksessa tutkittiin tsoledroninhapon ja korkea-annossytostaattihoidon mahdollista ennustetta parantavaa vaikutusta. Satunnaistaminen on nyt lopetettu ja potilaat hoidetaan hoitavan lääkärin harkinnan mukaisesti. Tutkimustulokset valmistuvat keväällä 2019.
Principal investigator: Jukka Kanerva
HUS Helsinki University Hospital, Comprehensive Cancer Center, Childern’s Hospital
ALL/FORUM – ACUTE LYMPHOPLASTIC LEUKEMIA
ALL SCTped 2012 FORUM: Allogeneic Stem Cell Transplantation in Children and Adolescents with Acute Lymphoblastic Leukaemia
Allogeeninen kantasolusiirto (SCT) lapsuusiän akuutin lymfoblastileukemian (ALL) hoidossa
Kyseessä on lasten allogeenisiin kantasolusiirtoihin liittyvä tutkimus-ja hoito-ohjelma, jossa yli 4-vuotiaat ALL potilaat satunnaistetaan esihoidon suhteen joko pelkän lääkehoidon (Treo/Flu/TT) tai säde-ja lääkehoidon (TBI/VP16) ryhmiin. Alle 4-vuotiaat saavat lääkkeellisen esihoidon. Kyseesssä on TBI:N suhteen ns. non-inferiority tutkimusasetelma
Principal investigator: Kim Vettenranta
HUS Helsinki University Hospital, Comprehensive Cancer Center, Childern’s Hospital
EWING relapsed SARCOMA
rEECur: International Randomised Controlled Trial of Chemotherapy for the Treatment of Recurrent and Primary Refractory Ewing Sarcoma
Kansainvälinen randomisoitu kontrolloitu tutkimus uusineen tai primaaristi refraktaarisen Ewining sarkooman kemoterapiasta
Tutkimuksen tarkoituksena on löytää paras mahdollinen lääkehoito vaikeaa Ewingin sarkoomaa sairastaville potilaille. Potilaat satunnaistetaan tutkimuksen alussa yhteen neljästä lääkehoitohaarasta.
Principal investigator: Jukka Kanerva
HUS Helsinki University Hospital, Comprehensive Cancer Center, Childern’s Hospital
B-NHL LYMPHOMA
B-NHL 2013: Treatment protocol of the NHL-BFM and the NOPHO study groups for mature aggressive B-cell lymphoma and leukemia in children and adolescents
Lapsuus-ja nuoruusiän kypsän B-solulymfooman ja Burkittin leukemian eurooppalainen hoito-ja tutkimusohjelma
Tavoitteena on parantuneiden potilaiden osuuden kasvattaminen lisäämällä hoitoon Rituximabi sekä haittavaikutusten vähentäminen korvaamalla osalla riskiryhmistä antrasykliinit Rituximabilla
Principal investigator: Pasi Huttunen
HUS Helsinki University Hospital, Comprehensive Cancer Center, Childern’s Hospital
NHL LYMPHOMA
Central nervous system involvement in non-Hodgin´s lymphoma among children and adolescents
Lapsuus-ja nuoruusiän non-Hodgkin-lymfooman leviäminen keskushermostoon
Tutkimme aiempaa herkemmillä diagnostisilla menetelmillä (virtaussytometria), kuinka yleistä on non-Hodgkin-lymfooman leviäminen keskushermostoon sekä selvitämme keskushermoston vähäisen lymfoomasolumäärän merkitystä taudin ennusteeseen. Kyseessä laaja kansainvälinen monikeskustutkimus.
Principal investigator: Kaisa Vepsäläinen Kuopio, Pasi Huttunen HUS
HUS Helsinki University Hospital, Comprehensive Cancer Center, Childern’s Hospital
GLIOBLASTOMA HR
M14-483 / 1414-BTG: A randomized phase II study of the EORTC Brain Tumor Group, ABT-414 alone or ABT-414 plus temozolomide versus lomustine or temozolomide for recurrent glioblastoma
Satunnaistettu II vaiheen tutkimus, jossa arvioidaan ABT-414 -valmistetta yksin tai yhdessä temotsolomidin kanssa verrattuna lomustiiniin tai temotsolimidiin potilailla,
joilla on uusiutunt glioblastooma
Tutkimuksen tavoitteena on arvioida parantaako ABT-414 yksin tai yhdessä temotsolomidin kanssa kokonaiselossaoloa, etenemisvapaata elossaoloa, kasvainvastetta,
elämänlaatua, elossaoloa ilman neurologista huononemista ja steroidien käyttöä verrattuna tavanomaiseen lomustiini-tai temotsolomidimonoterapiaan tai
temotsolomidiuusintahoitoon potilailla, joilla on keskitetysti arvioitu, uusiutunut glioblastooma, johon liittyy EGRF-amplifikaatio
Principal investigator: Virve Pentikäinen
HUS Helsinki University Hospital, Comprehensive Cancer Center, Childern’s Hospital
MEDULLOBLASTOMA LR ja SR
SIOP PNET 5 MEDULLOBLASTOOMA: AN INTERNATIONAL PROSPECTIVE STUDY ON CLINICALLY STANDARD-RISK MEDULLOBLASTOMA IN CHILDREN OLDER THAN 3 TO 5 YEARS WITH LOW-RISK BIOLOGICAL PROFILE (PNET 5 MB – LR) OR AVERAGE-RISK BIOLOGICAL PROFILE (PNET 5 MB -SR), SIOP PNET 5 Medulloblastoma
Kansainvälinen prospektiivinen tutkimus kliinisen standardiriskin medulloblastooman hoidosta yli 3-5 vuotiailla lapsilla, joiden kasvaimella on matalan riskin biologiset ominaisuudet
PNET5-MB-LR tai keskiriskin biologiset ominaisuudet PNET5-MB-SR
Kyseessä on kansainvälinen monikeskustutkimus, jonka tavoitteena on selvittää sädeherkistäjänä käytettävän karboplatiinin tehoa parantaa keskiriskin medulloblastoomapotilaiden ennustetta (PNET5 MB-SR sekä selvittää voiko matalariskin medulloblastoomapotilaiden (PNET5 MB-LR) hoidon intensiteettiä keventää ennusteen kärsimättä hoidon myöhäishaittojen vähentämiseksi
Principal investigator: Virve Pentikäinen
HUS Helsinki University Hospital, Comprehensive Cancer Center, Childern’s Hospital
HR NBL NEUROBLASTOMA
HR-NBL-1.8 / SIOPEN: High risk neuroblastoma study 1.8 of Siop-Europe (Siopen)
Korkean riskin neuroblastooma tutkimus Siopen
Kyseessä on lapsuusiän neuroblastooman tutkimus-ja hoito-ohjelmakokonaisuus, jonka ns. ylläpitovaiheessa potilaat saavat neuroblastoomasoluihin kohdennetun vasta-ainehoidon (anti-GD2, CH14.18/CHO) joko yhdessä aldesleukiinin (IL2) kanssa tai ilman sitä sekä syöpäsolukon kypsymistä edistävän (cis-retinoidi) lääkityksen tarkoituksella lisätä pysyvän remission todennäköisyyttä
Principal investigator: Kim Vettenranta
HUS Helsinki University Hospital, Comprehensive Cancer Center, Childern’s Hospital
